Clinical and Biological Sciences Department,
Neurology Unit,
Clinical and Biological Sciences Department, Neurology Unit
Luca Durelli has not added Biography.
If you are Luca Durelli and would like to personalize this page please email our Author Liaison for assistance.
Every-other-day interferon beta-1b versus once-weekly interferon beta-1a for multiple sclerosis: results of a 2-year prospective randomised multicentre study (INCOMIN).
Lancet (London, England) Apr, 2002 | Pubmed ID: 11988242
Intravenous immunoglobulin as first treatment in diabetics with concomitant distal symmetric axonal polyneuropathy and CIDP.
Journal of neurology Jun, 2002 | Pubmed ID: 12111305
Validation of diagnostic magnetic resonance imaging criteria for multiple sclerosis and response to interferon beta1a.
Annals of neurology Jun, 2003 | Pubmed ID: 12783417
Re: Vartanian T. An examination of the results of the EVIDENCE, INCOMIN, and phase III studies of interferon beta products in the treatment of multiple sclerosis. Clin Ther. 2003;25:105-118.
Clinical therapeutics Jun, 2003 | Pubmed ID: 12868445
Dose and frequency of interferon treatment matter--INCOMIN and OPTIMS.
Journal of neurology Dec, 2003 | Pubmed ID: 14712396
High-dose, frequently administered interferon beta therapy for relapsing-remitting multiple sclerosis must be maintained over the long term: the interferon beta dose-reduction study.
Journal of the neurological sciences Jul, 2004 | Pubmed ID: 15240190
Anti-interferon antibodies in multiple sclerosis. Molecular basis and their impact on clinical efficacy.
Frontiers in bioscience : a journal and virtual library Sep, 2004 | Pubmed ID: 15353281
Is multiple sclerosis a disease that requires frequent beta interferon dosing?
Journal of neurology Sep, 2004 | Pubmed ID: 15378303
Immunodetection of anti-MAG IgM antibody by cross-reactivity to LA-N-1 neuroblastoma cells.
Journal of neuroimmunology Apr, 2005 | Pubmed ID: 15748946
The importance of maintaining effective therapy in multiple sclerosis.
Journal of neurology Sep, 2005 | Pubmed ID: 16170500
A randomized study of two interferon-beta treatments in relapsing-remitting multiple sclerosis.
Neurology Dec, 2006 | Pubmed ID: 17190964
Interferon-beta1a for the treatment of multiple sclerosis.
Expert opinion on biological therapy Apr, 2007 | Pubmed ID: 17373904
Adherence to interferon-beta treatment and results of therapy switching.
Journal of the neurological sciences Aug, 2007 | Pubmed ID: 17376486
The therapy of multiple sclerosis with immune-modulating or immunosuppressive drug. A critical evaluation based upon evidence based parameters and published systematic reviews.
Clinical neurology and neurosurgery Nov, 2008 | Pubmed ID: 18164542
The OPTimization of interferon for MS study: 375 microg interferon beta-1b in suboptimal responders.
Journal of neurology Sep, 2008 | Pubmed ID: 18825438
Risk factors for tumor occurrence in patients with myasthenia gravis.
Journal of neurology Aug, 2009 | Pubmed ID: 19330280
T-helper 17 cells expand in multiple sclerosis and are inhibited by interferon-beta.
Annals of neurology May, 2009 | Pubmed ID: 19475668
Pro-inflammatory cytokine and chemokine mRNA blood level in multiple sclerosis is related to treatment response and interferon-beta dose.
Journal of neuroimmunology Sep, 2010 | Pubmed ID: 20573405
Th17 cells in multiple sclerosis express higher levels of JAK2, which increases their surface expression of IFN-γR2.
Journal of immunology (Baltimore, Md. : 1950) Feb, 2012 | Pubmed ID: 22219326
Use of Magnetic Resonance Imaging as Well as Clinical Disease Activity in the Clinical Classification of Multiple Sclerosis and Assessment of Its Course: A Report from an International CMSC Consensus Conference, March 5-7, 2010.
International journal of MS care , 2012 | Pubmed ID: 24453741
Treatment of relapsing-remitting multiple sclerosis after 24 doses of natalizumab: evidence from an Italian spontaneous, prospective, and observational study (the TY-STOP Study).
JAMA neurology Aug, 2014 | Pubmed ID: 24977406
Th22 cells are expanded in multiple sclerosis and are resistant to IFN-β.
Journal of leukocyte biology Dec, 2014 | Pubmed ID: 25097195
Epigenetic therapy for Friedreich ataxia.
Annals of neurology Oct, 2014 | Pubmed ID: 25159818
Long-term follow-up of ultrasound-guided botulinum toxin-A injections for sialorrhea in neurological dysphagia.
Journal of neurology Dec, 2015 | Pubmed ID: 26410746
Alemtuzumab long-term immunologic effect: Treg suppressor function increases up to 24 months.
Neurology(R) neuroimmunology & neuroinflammation Feb, 2016 | Pubmed ID: 26819963
Pierangelo Barbero1,
Marco Busso2,
Carlo Alberto Artusi1,
Stefania De Mercanti1,
Marco Tinivella3,
Andrea Veltri2,
Luca Durelli1,
Marinella Clerico1
1Clinical and Biological Sciences Department, Neurology Unit, University of Torino, San Luigi Gonzaga Hospital,
2Oncology Department, Radiology Unit, University of Torino, San Luigi Gonzaga Hospital,
3Clinical and Biological Sciences Department, Dietologic and Nutrition Unit, University of Torino, San Luigi Gonzaga Hospital
ABOUT JoVE
Copyright © 2024 MyJoVE Corporation. All rights reserved